Ironwood Pharmaceuticals (IRWD) Depreciation & Amortization (CF) (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $443000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 7.52% year-over-year to $443000.0; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (down 6.68% YoY), and the FY2025 full-year result was $1.1 million, down 8.33% from the prior year.
• Depreciation & Amortization (CF) fell to $443000.0 in Q1 2026, from $460000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $513000.0 in Q1 2024 to a low of $270000.0 in Q2 2023.
• A 5-year average of $431058.8 and a median of $467000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) retreated 25.0% in 2023 and soared 87.41% in 2024, its largest moves.
• Tracing IRWD's Depreciation & Amortization (CF) over 5 years: stood at $340000.0 in 2022, then surged by 50.59% to $512000.0 in 2023, then declined by 5.27% to $485000.0 in 2024, then dropped by 5.15% to $460000.0 in 2025, then declined by 3.7% to $443000.0 in 2026.
• Business Quant data shows IRWD's Depreciation & Amortization (CF) at $443000.0 in Q1 2026, $460000.0 in Q4 2025, and $475000.0 in Q3 2025.